NAD
This article was originally published in The Tan Sheet
Executive Summary
Novartis has halted use of claim that Rx Transderm Scop patch is "clinically proven more effective than Dramamine," CBBB division says in recent Case Report. Pharmacia brought the issue to NAD's attention, which recommended Novartis remove superiority claims from ads and provide a drowsiness disclaimer (1"The Tan Sheet" Nov. 13, 2000, p. 11). Following Novartis' unsuccessful appeal to NARB, NAD concludes firm has "made a good faith effort to comply" with advertising division's recommendations "in both its print advertising and redesigned Web site"...
|
Novartis has halted use of claim that Rx Transderm Scop patch is "clinically proven more effective than Dramamine ," CBBB division says in recent Case Report. Pharmacia brought the issue to NAD's attention, which recommended Novartis remove superiority claims from ads and provide a drowsiness disclaimer (1 (Also see "Novartis Transderm Scop Comparative Claims With Dramamine Denied By NAD" - Pink Sheet, 13 Nov, 2000.), p. 11). Following Novartis' unsuccessful appeal to NARB, NAD concludes firm has "made a good faith effort to comply" with advertising division's recommendations "in both its print advertising and redesigned Web site".... |